We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Haoma Medica

News List

Haoma Medica Completes First-in-Human Trial for Osteoporosis Treatment americanpharmaceuticalreview
December 14, 2020
Haoma Medica announced the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis.
Haoma Medica Completes First-in-Human Trial for NaQuinate, a Novel Treatment in Development for Osteoporosis prnasia
November 27, 2020
Haoma Medica announced today the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis.